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Abstract
Background : Cannabis is the most commonly used illegal drug and its therapeutic aspects have
a growing interest. Short-term psychotic reactions have been described but not clearly with
synthetic oral THC, especially in occasional users.
Case presentations: We report two cases of healthy subjects who were occasional but regular
cannabis users without psychiatric history who developed transient psychotic symptoms
(depersonalization, paranoid feelings and derealisation) following oral administration of cannabis. In
contrast to most other case reports where circumstances and blood concentrations are unknown,
the two cases reported here happened under experimental conditions with all subjects negative for
cannabis, opiates, amphetamines, cocaine, benzodiazepines and alcohol, and therefore the ingested
dose, the time-events of effects on behavior and performance as well as the cannabinoid blood
levels were documented.
Conclusion: While the oral route of administration achieves only limited blood concentrations,
significant psychotic reactions may occur.
Background
As several countries in Europe have taken policies to
decrease the penalties for cannabis possession, many peo-
ple especially young persons have interpreted this move as
giving support to consider cannabis as a benign drug [1].
However as stated by several reports cannabis is not a
harmless substance and requires urgent attention consid-
ering public health issues such as car driving for example
[2]. The relationship between Cannabis and acute psycho-
sis is another important issue. In Pakistan and also India,
Bhang, a beverage made from an infusion of cannabis
leaves, and flowering tops combined with milk and nuts
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is reported to frequently induce psychotic manifestations
among consumers [3]. Presenting symptoms include
grandiosity, excitement, hostility, uncooperativeness, dis-
orientation, hallucinatory behaviour and unusual
thought content [3].
Recently five large-scale longitudinal studies and a system-
atic review have shown that cannabis use in adolescence
is associated with a two-to threefold increase in the rela-
tive risk of later developing schizophrenia [4]. Further-
more short-term psychotic reactions, particularly in naive
users have also been reported. Thomas [5] describes that
one in seven people reported psychotic-like symptoms.
Such reactions are usually acute, transient, self-limited
however very unpleasant ("hearing voices, becoming con-
vinced that someone is trying to harm you or that you are
persecuted") [6]. But cannabinoids are considered able to
trigger long-lasting psychotic decompensations in predis-
posed individuals, which may in part account for the epi-
demiological association described between cannabis
consumption and psychotic disorders [7,8].
The therapeutic aspects of cannabis represent additional
issues, as they are in constant development since several
years. Synthetic THC (dronabinol) is available for
restricted medical use in the USA since 1985. Nabilone, a
synthetic THC analogue, is licensed in UK for the treat-
ment of nausea and vomiting caused by chemotherapy
unresponsive to usual anti-emetics. Clinical applications
actually include nausea and vomiting, muscle spasticity in
demyelinating diseases, loss of appetite in cancer and
AIDS, pain, insomnia, asthma as well as other applica-
tions [9].
As these oral medications are becoming increasingly avail-
able, we think it is useful to report two cases of severe psy-
chological sides effects, especially considering the lack of
data in the literature on psychotic symptoms associated
with oral synthetic or natural THC.
Case reports
We report two cases out of 8 healthy male volunteers who
were included in a double blind crossover clinical study,
approved by the ethics committee of the Department of
Internal Medicine of the University of Lausanne. All sub-
jects had to be occasional but regular cannabis users. Their
urines were controlled to be negative for any drug of abuse
(cannabis, opiates, amphetamines, cocaine, benzodi-
azepines) before each study period. The presence of etha-
nol was checked using a breathalyzer. All of them
provided their written informed consent. This study was
carried out to assess the effects of delta-9-tetrahydrocan-
nabinol (THC) on psychomotor function and driving per-
formance. It compared a medication containing 20 mg
dronabinol (MarinolR), and 2 hemp milk decoction con-
taining either a medium (15.8 mg average dose determi-
nation) or a high dose of THC (45.7 mg) with matched
placebos. The hemp plant fragments containing 1.5 %
THC and 4.4 % THC-A were provided by Hiscia institute
in Arlesheim, Switzerland. After administration, blood
was sampled at regular intervals for cannabinoids deter-
mination by gas chromatography coupled with mass spec-
trometry (GC-MS-NCI). Clinical observations and 2
psychometric tests (roadsign recognition speed and accu-
racy on a tracking task) were also carried out. Further-
more, the subjects were asked to report their willingness
to drive and the subjective effects on a VAS scale extending
from 0 to 10 cm. The effects were assessed against placebo.
These 2 cases were withdrawn from the study because of
adverse events. We consider them worth reporting for the
following reasons: in contrast to most other case reports
where circumstances and blood concentrations are not
known, our two cases reported here happened under
defined clinical setting: the ingested dose, the time-events
of effects on behavior and performance as well as the can-
nabinoid blood levels are fully documented. In addition,
the consumption of other psychotropic major drugs could
be ruled out.
Case 1
The first subject was a 22-year-old medical student
(weight: 65.3 kg, height: 1.82 m) and occasional cannabis
smoker (about once per week). One hour after the admin-
istration of 20 mg of dronabinol, he started to laugh a lot
and after 90 minutes, he manifested a severe anxiety with
symptoms of derealisation and depersonalization. He
reported "watching himself lying on the bed" and
repeated several times the same questions at just a few
minutes interval. Starting 2.5 hours after ingestion of dro-
nabinol, and at the 4 hours and 5.5 hours post-ingestion
series of tests, he was unable to perform the psychomotor
tasks, despite reporting of weakening of symptoms
approximately 165 minutes after their initiation. Before
going to sleep (more than 10 hours after ingestion), he
again felt a transient feeling of irrational anxiety and loos-
ing the perception of his body. The next day he was well
but a bit tired.
Figure 1 shows the evolution of his blood concentrations
of cannabinoids after ingestion of 20 mg dronabinol. At
the time of strong adverse effects, the blood levels of THC
and 11-OH-THC reached a concentration of 1.8 and 5.2
ng/mL, respectively. The subject reported a strong feeling
of intoxication (figure 2). He also evaluated that his driv-
ing capability was strongly impaired (figure 2).
Case 2
A 22-year-old student, also an occasional cannabis
smoker (about twice a month), felt paranoid delusionsBMC Psychiatry 2005, 5:17 http://www.biomedcentral.com/1471-244X/5/17
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with severe anxiety one hour after the administration of
16.5 mg of a THC decoction, and became suspicious dur-
ing the experiment. He thought the investigators were
concealing some problems. He was unable to perform the
psychometric tests (roadsign recognition speed and accu-
racy on a tracking task) at the 1 hour and 2.5 hours post-
ingestion series of tests. These effects persisted up to 4
hours after ingestion and weakened over the next 3 hours.
The feeling was very unpleasant in comparison with that
experienced after his usual smoking cannabis
consumption.
On the next day, he was well, with no recurrence. The
time-concentration curves for the major cannabinoids
were similar to those observed after ingestion of 20 mg
dronabinol. One hour after drinking the hemp decoction,
the THC and 11-OH-THC blood levels were of 6.2 and 3.9
ng/mL, respectively. Similarly to the other volunteer, he
also indicated a strong feeling of intoxication and a very
important decrease in his self-reported capacity to drive
(results not shown).
Conclusion
A temporary form of drug-induced psychotic reaction
after administration of oral cannabis has occurred in these
two cases. Cannabis psychosis is the term proposed in the
literature [10]. In 1958, Ames [11] reported in an experi-
mental design with 10 subjects psychological symptoms
such as severe anxiety, panic attacks, paranoid delusions
and depersonalization. Talbott [12] in 1969 described 12
soldiers in Vietnam who had disorientation and halluci-
nations after their first use of cannabis. In Germany, 19
cases of toxic psychosis were reported after hashish use
[13] and in Calcutta, Chopra [14] described
Whole blood concentrations of THC, 11-OH-THC (actives metabolites) and THC-COOH (inactive metabolite) after oral  intake of 20 mg dronabinol and of a hemp milk decoction containing traces of cannabinoids (placebo) Figure 1
Whole blood concentrations of THC, 11-OH-THC (actives metabolites) and THC-COOH (inactive metabolite) after oral 
intake of 20 mg dronabinol and of a hemp milk decoction containing traces of cannabinoids (placebo).
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retrospectively 200 patients hospitalized after the inges-
tion of large dose of cannabis between 1963 and 1968.
Other reports in different countries showed similar fea-
tures after bhang ingestion [3,15]. It usually results from
taking large amount of the drug, generally in food or
drink. The symptoms have some similarity with paranoid
schizophrenia, which could raise the hypothesis that "
symptoms of schizophrenic illness might be caused by an
abnormal over-activity of endogenous cannabinoid
mechanism in the brain" (Iversen [10] citing Emrich
[16]). However because of the poor quality of informa-
tion on previous cannabis experience, cannabis dose
intake, other drug consumption and previous psychiatric
comorbidity, some commentators have criticized these
case series [12,17,18]. Case-control studies have been
conducted comparing people with cannabis psychosis
with persons suffering from schizophrenia [19-21]. How-
ever the results were inconsistent due in part to the small
sample size of these studies.
The originality of our two cases is that they were observed
in an experimental setting, and therefore adds more evi-
dence for the ability of oral cannabis to produce psychotic
symptoms. In both our subjects, the effects appeared 1
hour to 1.5 hours after oral drug intake and lasted for 3 to
4 hours. Dronabinol (synthetic THC) is reported to have
an onset of action at approximately 0.5 to 1 hour and peak
effects between 2 and 4 hours. Psychoactive effects last 4
to 6 hours but the appetite stimulant effect may continue
for 24 hours [22].
The issue of THC dose level is very important in terms of
public health. A traditional cigarette of herbal cannabis in
the 1960s and 1970s contained 1–3% THC: for a joint
Subjective effects (feeling of intoxication or driving capability) after oral intake of 20 mg dronabinol Figure 2
Subjective effects (feeling of intoxication or driving capability) after oral intake of 20 mg dronabinol. The subject reported no 
feeling of intoxication or of driving impairment after ingestion of the placebo.
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made of 750 mg of cannabis plant, the corresponding
THC amount was 7 to 20 mg. However, the actual amount
of cannabis taken up (i.e. the percent delivery to the respi-
ratory tree) strongly depends on the smoking technique; it
has been reported to reach approximately 50% [23]. Mod-
ern cigarettes (joint) based on intensive cannabis selec-
tion and improvement in plant cultivation contain 6 to
30% THC. Therefore, an average joint would correspond
to 75 mg to 225 mg of THC! [22].
Through smoking, a 3.5% marijuana cigarette with about
900 mg plant materials can achieve plasma concentration
in the range of 50 to 100 ng/ml. The maximum psycho-
tropic effect or "high" occurs faster after smoking than by
the oral route. Smoking is therefore the preferred route of
cannabis administration for young users. Psychomotor
function is considered to be obviously impaired above 10
ng/ml plasma THC for smoking cannabis. However in our
two cases, the oral administration of cannabis produced
circulating THC concentrations much lower than 10 ng/
ml. We suggest several explanations for these differences.
Firstly, the oral administration produces more active
metabolite (11-OH-THC), which could more efficiently
reach the effect site than THC. Secondly, as suggested by
Chaudry [3], consuming oral cannabis may produce more
potent, yet unknown psychotomimetic metabolites of
THC. Thirdly, the slow absorption kinetics produces sus-
tained plateau levels in the blood, which could influence
the body and brain distribution. In a cocaine fatality, Gir-
oud [24] found that THC and OH-THC were in higher
concentration in brain than in blood.
Finally, Leweke [25] in a study including 17 healthy vol-
unteers found also one case that suffered a two-hour epi-
sode of paranoid psychotic state following the
administration of dronabinol with a lower dose than our
study. Furthermore D'Souza [26] administrating intrave-
nous THC to 22 healthy subjects in a double blind ran-
domised clinical trial found a range of transient
symptoms resembling those seen in endogenous psycho-
sis. At last, it is important to differentiate these transient
psychotic states with spontaneous resolution from the
type of psychosis that persist beyond the persistence of
drug in the brain, therefore probably indicating a worsen-
ing of an underlying pathologic problem.
In conclusion, doctors and users should be aware of the
increasing availability of oral cannabis in "special" drinks
or food as well as in medications under development.
While the oral route of administration achieves only lim-
ited blood concentrations, significant psychotic reactions
may occur. An increased incidence of psychotic episodes
might be induced by this new trend and requires attention
regarding this phenomenon in a public health
perspective.
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